Oragenics, Inc. Overview
Pro stress-test →Oragenics is a development-stage company engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. The company's lead candidate, ONP-002, is advancing with the goal of becoming the first FDA-approved treatment for concussion.
Strategic Profile
Pro stress-test →Oragenics is striving to revolutionize neurological care through proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. The company closed a $16.5 million Series H convertible preferred stock offering on July 2, 2025, which restored equity and provides runway to advance lead candidate ONP-002 through Phase IIa in Australia and to prepare for potential U.S. Phase IIb trials.
Competitive Landscape
Pro stress-test →Oragenics faces competition from other neurological drug developers and brain-targeted therapeutic companies. Its proprietary intranasal delivery platform differentiates it, but it competes with both established pharma companies developing concussion treatments and other biotech firms pursuing neurology indications.
Industry Context
Oragenics, Inc. operates in Biopharmaceutical - Clinical-stage development focusing on neurological disorders and brain-targeted therapeutics.
Key facts
Headquarters: United States